Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 35Terminated 9Withdrawn 4Recruiting 2Active not recruiting 2No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Biphenotypic, Acute 10Leukemia, Myelomonocytic, Chronic 9Hematologic Neoplasms 8Hodgkin Disease 6Myeloproliferative Disorders 5Lymphoma, Non-Hodgkin 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Lymphoma, T-Cell 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Graft vs Host Disease 3Burkitt Lymphoma 3Anemia, Refractory, with Excess of Blasts 3Primary Myelofibrosis 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myeloid 2Leukemia, Monocytic, Acute 2Leukemia, Lymphoid 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Thrombocythemia, Essential 1Sarcoma, Ewing 1Rhabdomyosarcoma 1

Interventions

Rituximab 22Lenalidomide 13orelabrutinib 12obinutuzumab 11Cyclophosphamide 9zanubrutinib 8fludarabine 7Magnetic Resonance Spectroscopy 5Bendamustine Hydrochloride 5venetoclax 4Specimen Handling 4Biopsy 4pirtobrutinib 3fludarabine phosphate 3Whole-Body Irradiation 2Vincristine 2Stem Cell Transplantation 2Prednisone 2Mycophenolic Acid 2CT-P10 2Automobiles 2treosulfan 1tafasitamab 1polatuzumab vedotin 1pemigatinib 1loncastuximab tesirine 1ibrutinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell, Marginal Zone × Whole-Body Irradiation × Clear all
NCT04195633 2026-05-29

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡